Danaher Corporation ($DHR) Stock Forecast: Down 5.1% Today

What is Danaher Corporation?

Danaher Corp (NYSE: DHR) is an industrial and medical device maker that recently announced its Q4 2025 financial results. The company outperformed in adjusted EPS but fell slightly short on revenue.

Why is Danaher Corporation going down?

DHR stock is down 5.1% on Jan 28, 2026 19:45

• Danaher Corp's Q4 2025 earnings showed a mixed outcome, surpassing expectations in EPS but missing revenue targets. This led to a 1.4% decline in the company's shares.
• The strong performance in the bioprocessing business and positive earnings were overshadowed by the slight revenue miss, which might have sparked concerns among investors.
• Analysts are bullish on Danaher Corp's growth trajectory for 2026, with revenue and EPS projections indicating a return to growth that could potentially restore investor confidence.
• Investor sentiment following the earnings announcement underscored a focus on revenue metrics and a cautious stance on the company's future prospects, contributing to the downward movement in DHR stock.

DHR Price Chart

DHR Technical Analysis

DHR News

Danaher Corp (NYSE:DHR) Q4 2025 Earnings: Revenue Miss Offsets EPS Beat, Shares Dip

Danaher Corp (NYSE:DHR) reported its Q4 2025 earnings, revealing an EPS beat of $2.23 against an estimated $2.17, but a slight revenue miss of $6.84 billion compared to the anticipated $6.87 billion. This mixed performance led to a 1.4% dip in shares during pre-market trading, as investors weigh the revenue shortfall against the earnings beat. Analysts are now looking to 2026, with revenue and EPS estimates pointing towards resumed growth for the conglomerate.

https://www.chartmill.com/news/DHR/Chartmill-40540-Danaher-Corp-NYSEDHR-Q4-2025-Earnings-Revenue-Miss-Offsets-EPS-Beat-Shares-Dip

DANAHER ($DHR) Releases Q4 2025 Earnings

Danaher ($DHR) reported its Q4 2025 earnings, posting $2.23 per share, which beat estimates, but revenue of $6.838 billion missed expectations. The article also details recent insider trading, hedge fund activity, government contracts won by Danaher, congressional stock trades involving DHR, and a compilation of recent analyst ratings and price targets for the company.

https://www.quiverquant.com/news/DANAHER+%28%24DHR%29+Releases+Q4+2025+Earnings

Danaher: Q4 Earnings Snapshot

Danaher Corp. reported net income of $1.2 billion in its fourth quarter, totaling $1.68 per share, or $2.23 adjusted per share. The industrial and medical device maker exceeded revenue forecasts with $6.84 billion. For the full year, Danaher reported a profit of $3.61 billion, or $5.05 per share, on revenue of $24.57 billion, and projects full-year earnings between $8.35 and $8.50 per share.

https://www.king5.com/article/syndication/associatedpress/danaher-q4-earnings-snapshot/616-30af2238-59fb-4ff0-9a96-1ab3ea699a6f

Danaher beats Q4 expectations as bioprocessing business shows strength

Danaher Corporation reported stronger-than-expected fourth-quarter and full-year 2025 results, with adjusted EPS of $2.23 and revenue of $6.84 billion for Q4, driven by strong bioprocessing performance. Despite the positive report, shares saw a slight dip. The company projects low-single digit non-GAAP core revenue growth for Q1 2026 and expects full-year 2026 core revenue growth of 3% to 6%, with adjusted EPS between $8.35 and $8.50.

https://www.investing.com/news/earnings/danaher-beats-q4-expectations-as-bioprocessing-business-shows-strength-4469625

Danaher Q4 Earnings Exceed Expectations

Danaher (DHR) reported Q4 non-GAAP EPS of $2.23, surpassing expectations by $0.04, and revenue of $6.84 billion, a 5.2% year-over-year increase. The company projects low single-digit core sales growth for 2026, with biotechnology contributing significantly, and adjusted diluted net earnings per share are expected to be between $8.35 and $8.50. Wall Street analysts maintain a positive outlook, with an average 1-year price target of $261.57.

https://intellectia.ai/news/stock/danaher-q4-earnings-exceed-expectations

Trending Today

S&P 500 Index ($SPX) Index Forecast: Down 0.2% Today

Silver ($XAG) Commodity Forecast: Up 5.7% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.9% Today

Danaher Corporation Price History

13.00.2026 - DHR Stock was down 2.9%

• The decline in Danaher Corporation's stock today, despite positive earnings and growth projections, may be linked to profit-taking by institutional investors and notable reductions in their stake.
• Insider sales by company executives, including SVP Brian W. Ellis and Director Teri List, could also have played a role in the stock's downward trend.
• Market reaction might be influenced by reports of Danaher Corp. co-founder Mitch Rales spearheading a significant funding round for VieCure, diverting attention from the company's core operations and creating uncertainty for investors.
• While Danaher continues to demonstrate strong financial performance and provide optimistic guidance for the future, recent developments in institutional holdings and external investments may have instigated bearish sentiment in the market today.

21.09.2025 - DHR Stock was up 6.3%

• Danaher (DHR) reported Q3 earnings and sales that surpassed expectations, with a significant increase in Life Sciences sales compared to the previous year.
• The strong segment growth and enhanced operating margins contributed to the favorable financial results, indicating effective management and strong market demand for the company's offerings.
• Optimistic assessments and future forecasts from financial analysts prior to the earnings announcement likely influenced investor confidence in Danaher's performance, leading to a positive upward trend in the stock price.
• In summary, the robust Q3 results and promising outlook indicate that Danaher's strategic initiatives and market positioning are well-received by investors, prompting a rise in the stock value.

21.09.2025 - DHR Stock was up 11.0%

• Danaher (DHR) reported Q3 earnings and revenues that surpassed expectations, reflecting strong financial performance.
• Analyst insights prior to the earnings announcement likely bolstered investor confidence in the company's growth prospects.
• Despite initial doubts, Danaher's positive earnings and optimistic future outlook drove the stock's upward momentum as investors reassessed the company's potential for success.

05.00.2026 - DHR Stock was up 0.4%

• Danaher's strategic shift towards higher-margin life sciences and diagnostics is positively impacting investor sentiment and driving the bullish movement.
• The increased stake by Railway Pension Investments Ltd signals confidence in Danaher's future prospects and strong Q3 earnings performance.
• Despite potential risks from early-stage biotech funding weakness, the company's focus on profitable segments and positive analyst ratings are contributing to the stock's upward momentum.
• Overall, the market seems optimistic about Danaher's growth potential and strategic direction, leading to the bullish movement in its stock price.

13.10.2025 - DHR Stock was up 3.4%

• Danaher (DHR) observed a bullish movement today, potentially linked to investors acknowledging its value relative to its competitor Solventum (SOLV).
• Comparative analysis between SOLV and DHR could explain the heightened interest in DHR, resulting in increased buying activity.
• Investors might have identified DHR as the more advantageous stock at present, propelling its price upward.
• The optimistic outlook on DHR's potential value likely played a role in its significant bullish movement today.

02.00.2026 - DHR Stock was up 1.5%

• The bullish movement in Danaher's stock can be attributed to the positive market outlook for bioprocess filtration and single-use bioprocessing products, with recent reports projecting significant market growth driven by increasing demand for biologics and advanced therapies.
• Vanderbilt University acquiring a substantial number of shares in Danaher Corporation further boosted investor confidence, indicating strong institutional interest in the company's performance and potential.
• Danaher's solid Q3 earnings report, surpassing analyst expectations for both earnings per share and revenue, coupled with the announcement of a quarterly dividend, likely contributed to the positive sentiment surrounding the stock.
• The recognition of Danaher as a key player in the bioprocess filtration market alongside competitors like Merck and Sartorius underscores the company's position as a leader in the industry, attracting both investor attention and market confidence.

21.04.2025 - DHR Stock was down 5.1%

• The bearish movement in DHR stock today could be due to profit-taking by investors following a recent increase in the stock price.
• The significant decline in the stock price over the past year might also have influenced bearish sentiment among investors.
• Insights from the P/E ratio reveal a decrease of 25.98% in the last year, potentially adding to selling pressure on the stock.
• Investor caution could be stemming from the mixed performance of the stock despite recent gains, prompting a bearish market movement today.

15.04.2025 - DHR Stock was down 5.5%

• Investors may have reevaluated their positions due to a value comparison between CVS Health and Danaher, potentially leading to a sell-off in the stock.
• The market sentiment towards the Medical Services sector might have shifted, negatively impacting Danaher's stock price.
• Uncertainty surrounding Danaher's future growth prospects or financial performance could be a contributing factor to today's bearish movement.

28.00.2026 - DHR Stock was down 5.1%

• Danaher Corp's Q4 2025 earnings showed a mixed outcome, surpassing expectations in EPS but missing revenue targets. This led to a 1.4% decline in the company's shares.
• The strong performance in the bioprocessing business and positive earnings were overshadowed by the slight revenue miss, which might have sparked concerns among investors.
• Analysts are bullish on Danaher Corp's growth trajectory for 2026, with revenue and EPS projections indicating a return to growth that could potentially restore investor confidence.
• Investor sentiment following the earnings announcement underscored a focus on revenue metrics and a cautious stance on the company's future prospects, contributing to the downward movement in DHR stock.

22.06.2025 - DHR Stock was down 1.3%

• Earnings and revenue figures for Q2 exceeded expectations for Danaher (DHR), with market volatility potentially linked to concerns in the Life Sciences area.
• Strong performance in the Biotechnology & Diagnostics divisions alongside the recent acquisition of Abcam are viewed as factors that could drive future growth for the company.
• Analyst commentary on Q2 performance metrics for Danaher (DHR) may have impacted market sentiment, contributing to the stock's downward movement today.

23.06.2025 - DHR Stock was up 5.0%

• Danaher showed strong bullish movement today following its impressive Q2 earnings, where it exceeded sales and EPS estimates, demonstrating robust performance in its biotech segment.
• The company's positive outlook for 2025, driven by biotech growth and cost discipline, has boosted investor confidence, resulting in a rise in the stock price.
• Analysts' optimistic views and projections for Danaher's key performance indicators further reinforce the positive sentiment surrounding the stock, pointing towards a promising future in the biotechnology and diagnostics sectors.

30.08.2025 - DHR Stock was up 5.2%

• Danaher Inc.'s stock price surged by 1.05% today, reflecting strong bullish momentum.
• Despite recent declines over the past month and year, today's uptick indicates a resurgence of investor confidence.
• The rise in stock price could be linked to potential undervaluation, prompting shareholders to seize the opportunity.
• Investors show optimism regarding Danaher's future prospects and growth across its various business segments, propelling the stock price upwards.